Table 4

Discriminative validity in the ASPIRE and ATTRACT trials at 6 months.

ASPIREATTRACT
SDAI response categoryMTXMTX+IFXp ValuePLCIFXp Value
SDAI5065.2%77.8%1.4×10−325.7%60.6%2.3×10−4
SDAI7039.8%55.8%3.3×10−410.0%32.2%7.9×10−3
SDAI8514.4%30.2%5.2×10−55.5%10.6%4.2×10−1
ACR2059.9%73.4%4.8×10−440.9%60.0%2.9×10−2
ACR5036.5%55.7%5.5×10−613.6%32.3%2.1×10−2
ACR7016.3%32.5%2.1×10−54.5%12.2%2.3×10−1
  • ACR, American College of Rheumatology; IFX, infliximab; MTX, methotrexate; SDAI, simplified disease activity index.